Hims & Hers Health (HIMS) heads into Q1 earnings with shares up 49.6% over past month

Hims & Hers Health (NYSE: HIMS) is scheduled to report first-quarter results after the market close on May 18, 2026, with Wall Street expecting revenue growth of 5.2% year over year, a sharp slowdown from 111% growth in the year-earlier quarter. The telehealth company reported $617.8 million in revenue in the prior quarter, up 28.4% from a year earlier and in line with analyst expectations. The company added 40,000 customers, bringing its total to 2.51 million, while full-year revenue guidance topped estimates and near-term guidance missed expectations. Investor sentiment toward health care technology stocks has improved, with the group up 6.1% over the past month. Hims & Hers shares have risen 49.6% in that period and recently traded at $29.07, above the average analyst price target of $26.04. Peer results have been mixed: GoodRx revenue fell 4.4% but beat estimates, while Tandem Diabetes revenue rose 5.5% and also topped expectations.